Clinical observastion of Bushen-Qiangjin capsule and calcium D on aromatase inhibitors-induced osteopenia in breast cancer patients
10.3760/cma.j.issn.1673-4246.2018.06.007
- VernacularTitle:补肾强筋胶囊联合钙尔奇D对乳腺癌芳香化酶抑制剂相关骨丢失患者骨代谢的影响
- Author:
Suwen ZOU
1
;
Zhitao GUO
;
Ying ZHONG
;
Xuezhen LI
;
Yingfei HUANG
Author Information
1. 510405,广州中医药大学第五临床医学院
- Keywords:
Breast neoplasms;
Bushen-Qiangjin capsule;
Aromatase inhibitors;
Bone density;
Osteocalcin;
Tartrate-resistant acid phosphatase
- From:
International Journal of Traditional Chinese Medicine
2018;40(6):507-509
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical effect of the Bushen-Qiangjin capsule and calcium D in the treatment of aromatase inhibitors-associated bone loss (AIBL) in breast cancer patients. Methods A total of 65 patients were randomized into a treatment group and a control group, 32 in the control group taking calcium D, and 33 in the treatment group taking calcium D and Bushen-Qiangjin capsule. After a 3-month treatment, the bone mineral density T (BMD), bone-specific alkaline phosphatase (BALP), bone gla protein (BGP) and tartrate resistant acid phosphatase (TrACP) of two groups were evaluated. Results The BMD increased significantly after treatment in both groups (P<0.05), and the therapeutic efficacy of the treatment group was better than of the control group (P<0.05). After treatment, the level of BALP (308.76 ± 10.99 U/L vs. 280.00 ± 7.44 U/L, t=8.170) and the BGP (42.21 ± 3.04 ng/ml vs. 34.38 ± 2.06 ng/ml, t=6.818) of the treatment group were significantly higher than those of the control group (P<0.01). The level of TrACP decreased significantly after treatment in both groups (P<0.05), and the TrACP (60.12 ± 4.58 U/L vs. 67.25±4.06 U/L, t=1.653) of treatment group was significantly lower than that of the control group (P<0.05). Conclusions The Bushen-Qiangjin capsule can produce a content efficacy in treating AIBL in breast cancer patients, improving the BMD and bone metabolism.
